Adrenomed AG is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: developing precision medicine to rescue vascular integrity and saving the lives of critically ill patients with limited treatment options. The Company’s lead product candidate is Adrecizumab, a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity, to treat life-threatening conditions associated with increased vascular leakage, congestion and shock. Our current lead indications are sepsis and septic shock. We translate the concept of precision medicine into acute care. Our biomarker-guided approach enables us to identify the patients with loss of vascular integrity as an underlying pathophysiological disease mechanism and to treat patients that will most likely benefit from Adrecizumab therapy.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Globally (various continents)
- Year Founded:
Adrenomed’s business is effectively secured by a strong IP position with granted patents in all major markets.
Adrenomed is based in Hennigsdorf near Berlin, Germany.
Adrenomed was established in 2009 after the successful trade sale of the B·R·A·H·M·S AG to Thermo Fisher. The co-founders and executive managers of the B·R·A·H·M·S AG were Dr. Andreas Bergmann, who serves today as CSO of Adrenomed; also Dr. Bernd Wegener and Dr. Metod Miklus, who today are members of Adrenomed’s Supervisory Board. At B·R·A·H·M·S AG they changed the standard of care in sepsis by developing Procalcitonin (B·R·A·H·M·S PCTTM), the diagnostic gold standard sepsis biomarker.
The extensive in-depth work in sepsis, diagnostics and drug development led to well-established contacts with key opinion leaders worldwide in cardiovascular disease and sepsis that support Adrenomed’s clinical research.